

NOTICE TO CONVENE THE ANNUAL GENERAL MEETING

DANSK BIOTEK

(CVR no. 28 43 65 72)

Notice is hereby given to the Annual General Meeting of DANSK BIOTEK to be held on

Thursday 7 May, 2020, at 15:00 (CET) at Plesner Advokatpartnerselskab Amerika Plads 37, 2100 København Ø

<u>Due to the outbreak of coronavirus/covid-19, all members are urged to give power of attorney to Plesner's Thomas Holst Laursen on thl@plesner.com, and not to attend the general meeting in person.</u>

The agenda is as follows:

- a) Election of chairman of the annual general meeting
- b) Chairman's statement
- c) Approval of financial result for 2019
- d) Determination of membership fee for 2020
- e) Election of chairman
- f) Election of other members of the board
- g) Election of auditor
- h) Discussion of proposals
- i) Any other business

Re a) - Election of chairman of the annual general meeting

Election of Chairman of the Annual General Meeting.

Re b) - Chairman's statement

Chairman Hans Schambye makes his statement regarding the previous year.

Re c) - Approval of financial result for 2019

The Board proposes that the annual report with the auditor's report for 2019 is approved.

Re d) - Determination of membership fee for 2020

The Board proposes that the membership fee for 2020 shall be unchanged compared with 2019.

Re e) - Election of chairman

The Chairman is elected for a two-year period and may be re-elected.

The Board proposes that Hans Schambye continues as Chairman.

Re f) - Election of other members of the board

The Board is elected for a two-year period and may be re-elected.

The Board of directors proposes re-election of the following board members, who stand for election:

- Alejandra Mørk, CEO, KLIFO A/S (2018-2020)
- Henrik Blou, CEO, Gubra (2018-2020)
- Henrik Dalbøge, various directorships (2018-2020)
- Søren Møller, Managing Investment Director, Novo A/S (2018-2020)

The following board members continue:

- Mai-Britt Zocca, CEO & founder, IO Biotech ApS (2019-2021)
- Adam Steensberg, Executive Vice President, Zealand Pharma A/S (2019-2021)
- Anders Hinsby, Biotech Entrepreneur, BiOrigin (2019-2021)

Re g) - Election of auditor

The Board proposes re-election of Ernst & Young Godkendt Revisionspartnerselskab, CVR no. 30 70 02 28 as the auditor of DANSK BIOTEK.

Re h) - Discussion of proposals

No proposals received to be discussed.

Re i) - Any other business

Any other business.

- 0 -

Kind regards

The Board of DANSK BIOTEK